Our Company

Our Mission

“We will cure cancers and save lives with our innovative and widely accessible immunotherapies.”

Our Story

Tessa’s story started over 20 years ago, when Dr. Malcolm Brenner, our co-founder, and his team at Baylor College of Medicine embarked on a journey to better understand and harness the body’s natural anti-viral immune response. Their research led to the development of our platform technology – Virus-Specific T cells (VST).

Initial VST trials held promising results – including TT10 Phase II trial at National Cancer Centre Singapore (NCCS) which produced the best published 2-year survival data in patients with advanced NPC. This set the stage for the pivotal Phase III trial, which is the world’s largest T cell therapy trial for any cancer indication with 330 patients across 30 hospitals and 4 labs in 5 countries.

Today, Tessa has expanded our pipeline to target multiple cancer indications, building next generation technologies on our core VST platform. We are proud to be spearheading innovation in the field of cancer immunotherapy for solid tumors and are committed to working towards our vision of a world without untreatable cancers.

Our Values

Think Beyond

We are innovative and are active problem solvers. We think and go beyond the obvious. We have the courage to speak up.

Strive to Excel

We pursue excellence and overcome challenges with resilience. We work passionately towards our mission.

Do What’s Right

We are guided by integrity and ethics to do what is right. We deliver on our promises. We value honesty and transparency.

Care Deeply

Our patients are at the heart of what we do. We care deeply about the impact that our work has on others.